Abstract
The bispecific therapeutic antibody blinatumomab links CD3+ cytotoxic T-cells to CD19+ B-cells, including B-cell acute lymphoblastic leukemia (ALL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have